NZAGRC Changes Name To Ag Emissions Centre
The new name is about being more visible, better connected, and more easily identified by the farmers, Mori agribusinesses, researchers, and industry partners we support. It reflects the Centres role as specialists in agricultural emissions, and the …
The New Zealand Agricultural Greenhouse Gas Research Centre (NZAGRC) has a new name. It will now be known as the Ag Emissions Centre.
Since 2009, the Ag Emissions Centre has led research to help farmers meet the growing challenge of agricultural greenhouse gas emissions. The new name will make it easier for farmers and industry to find and engage with the science, tools, and support that will help them reduce emissions.
'As international expectations around emissions have grown, so too has the pressure on farmers to respond, and our work has evolved alongside them,' says Dr Naomi Parker, Executive Director of the Ag Emissions Centre.
'The new name is about being more visible, better connected, and more easily identified by the farmers, Māori agribusinesses, researchers, and industry partners we support. It reflects the Centre's role as specialists in agricultural emissions, and the urgency of the challenge we're helping tackle.'
While the name has changed, the Ag Emissions Centre's core mission remains the same: shaping and funding research that can help farmers, government, and industry meet global demands for low-emissions farming. Its research portfolio includes a methane vaccine and inhibitors, nitrous oxide inhibitors, low-methane livestock genetics, and farm systems research.
Reducing agricultural emissions remains one of the most pressing issues facing New Zealand's primary sector. Agriculture makes up over 50% of the country's total emissions, and the pressure to demonstrate measurable reductions from global markets, customers, and trading partners is growing.
'Farmers are already feeling the effects of climate change and shifting market expectations,' says Dr Parker. 'Our role is to help discover and develop the tools and knowledge New Zealand farmers need to stay competitive, protect their markets, and keep farming sustainably into the future.'
The Ag Emissions Centre will continue to operate as an independent unit within AgResearch, which will transition on 1 July 2025 to the new Bioeconomy Science Institute under the Government's wider science system reform.
Existing contracts and relationships with research partners remain unchanged. Stakeholders will begin seeing the new name and branding, including new email addresses and website at ag-emissions.nz from 1 July 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scoop
a day ago
- Scoop
Project Aims To Bring Cutting-Edge Cancer Treatments To NZ
Press Release – University of Auckland Cell-based therapies are the most advanced and promising treatments for cancer,' says Didsbury, who is an immunologist, committee chair at the International Society for Cell and Gene Therapy, and a trustee for Ovarian Cancer Foundation NZ. Plans are under way to bring life-saving cell-based cancer treatments to patients in New Zealand. Dr Alicia Didsbury from the University of Auckland's Centre for Cancer Research is leading a major project aiming to provide cell and gene therapies for cancer. The project is supported by the New Zealand Blood Service and doctors at Auckland City Hospital. Didsbury is applying for $1.4 million for the first phase of the project, which will offer virus-specific T-cell therapy for people with blood cancers who are undergoing treatments that lower their immunity. Virus-specific T-cells fight viruses more effectively and with fewer side effects than antiviral medications, which are currently used widely. The aim is for the first phase to begin later this year, establishing the country's first facility to manufacture virus-specific T-cells and a local biobank of T-cells. From there, the plan is to launch New Zealand's first clinical trials of cell-based treatments for a broad range of blood cancers and solid tumour cancers over the next few years. 'Cell-based therapies are the most advanced and promising treatments for cancer,' says Didsbury, who is an immunologist, committee chair at the International Society for Cell and Gene Therapy, and a trustee for Ovarian Cancer Foundation NZ. 'At the moment, access to cellular therapies is extremely limited in New Zealand, so some patients go overseas and have to pay hundreds of thousands of dollars for these life-saving treatments.' Blood-cancer patients who receive stem-cell transplants are generally given immune suppressant medication to prevent complications. This can leave patients vulnerable to potentially life-threatening viral infections. New Zealand currently imports a small number of virus-specific T-cells, but these are expensive and not always a good match for Māori and Pacific populations, says Didsbury. 'By manufacturing virus-specific T-cells here in Auckland, we can create more affordable and better-matched therapies using local donor cells,' says Didsbury. 'For some people undergoing transplants, this could be lifesaving.' Launching a virus-specific T-cell manufacturing and treatment service in Auckland will help build the basis to launch national and international clinical trials for cell-based treatments for blood and solid tumour cancers. The second phase of the project will make experimental treatments for multiple myeloma, melanoma, ovarian and lung cancers available in New Zealand for the first time. 'I'm a strong advocate for clinical trials in cancer care. They offer hope to patients and contribute to research that brings hope to others in the future,' says Didsbury. Initially, the project will launch at Auckland Hospital, but Didsbury hopes clinical trials will later be offered throughout New Zealand. For blood cancers, cell-based therapies show remarkable results. For solid tumours, cellular treatments are more experimental and have only completely cured a small percentage of patients in overseas trials. CAR T-cell therapy is one of the most promising treatments that will be offered. It harnesses the natural ability of T-cells – white blood cells that normally detect and kill virus-infected cells – to target cancer. In this therapy, a patient's own T cells are collected and genetically modified in the lab to recognise and kill cancer cells. These modified cells are then infused back into the patient to fight the cancer. CAR T-cell therapy can currently cost more than $500,000 per patient, so the project will explore affordable ways to offer these treatments within the public health system. The new service also aims to offer other cell and gene-based cancer therapies, such as transgenic T-cell receptor therapy and tumour-infiltrating lymphocyte therapy. Didsbury's drive to make cancer treatments more accessible and affordable has personal roots. 'My dad passed away from cancer when I was 21 and that motivated me to pursue a career in cancer research – initially thinking I'd go into drug discovery. 'Then, in 2005, I attended a lecture from a scientist who had recently returned from Oxford who introduced me to the new idea of T-cell therapy – that was Professor Rod Dunbar. It completely changed my direction. I decided to do a PhD with him and he's still my boss at the University of Auckland's School of Biological Sciences,' she says. The 46-year-old has been developing cell-based treatments for cancer for 15 years. A breakthrough treatment she helped develop for melanoma could soon be offered in clinical trials.
Scoop
a day ago
- Scoop
Project Aims To Bring Cutting-Edge Cancer Treatments To NZ
Plans are under way to bring life-saving cell-based cancer treatments to patients in New Zealand. Dr Alicia Didsbury from the University of Auckland's Centre for Cancer Research is leading a major project aiming to provide cell and gene therapies for cancer. The project is supported by the New Zealand Blood Service and doctors at Auckland City Hospital. Didsbury is applying for $1.4 million for the first phase of the project, which will offer virus-specific T-cell therapy for people with blood cancers who are undergoing treatments that lower their immunity. Virus-specific T-cells fight viruses more effectively and with fewer side effects than antiviral medications, which are currently used widely. The aim is for the first phase to begin later this year, establishing the country's first facility to manufacture virus-specific T-cells and a local biobank of T-cells. From there, the plan is to launch New Zealand's first clinical trials of cell-based treatments for a broad range of blood cancers and solid tumour cancers over the next few years. 'Cell-based therapies are the most advanced and promising treatments for cancer," says Didsbury, who is an immunologist, committee chair at the International Society for Cell and Gene Therapy, and a trustee for Ovarian Cancer Foundation NZ. 'At the moment, access to cellular therapies is extremely limited in New Zealand, so some patients go overseas and have to pay hundreds of thousands of dollars for these life-saving treatments.' Blood-cancer patients who receive stem-cell transplants are generally given immune suppressant medication to prevent complications. This can leave patients vulnerable to potentially life-threatening viral infections. New Zealand currently imports a small number of virus-specific T-cells, but these are expensive and not always a good match for Māori and Pacific populations, says Didsbury. 'By manufacturing virus-specific T-cells here in Auckland, we can create more affordable and better-matched therapies using local donor cells,' says Didsbury. 'For some people undergoing transplants, this could be lifesaving." Launching a virus-specific T-cell manufacturing and treatment service in Auckland will help build the basis to launch national and international clinical trials for cell-based treatments for blood and solid tumour cancers. The second phase of the project will make experimental treatments for multiple myeloma, melanoma, ovarian and lung cancers available in New Zealand for the first time. 'I'm a strong advocate for clinical trials in cancer care. They offer hope to patients and contribute to research that brings hope to others in the future,' says Didsbury. Initially, the project will launch at Auckland Hospital, but Didsbury hopes clinical trials will later be offered throughout New Zealand. For blood cancers, cell-based therapies show remarkable results. For solid tumours, cellular treatments are more experimental and have only completely cured a small percentage of patients in overseas trials. CAR T-cell therapy is one of the most promising treatments that will be offered. It harnesses the natural ability of T-cells – white blood cells that normally detect and kill virus-infected cells – to target cancer. In this therapy, a patient's own T cells are collected and genetically modified in the lab to recognise and kill cancer cells. These modified cells are then infused back into the patient to fight the cancer. CAR T-cell therapy can currently cost more than $500,000 per patient, so the project will explore affordable ways to offer these treatments within the public health system. The new service also aims to offer other cell and gene-based cancer therapies, such as transgenic T-cell receptor therapy and tumour-infiltrating lymphocyte therapy. Didsbury's drive to make cancer treatments more accessible and affordable has personal roots. 'My dad passed away from cancer when I was 21 and that motivated me to pursue a career in cancer research – initially thinking I'd go into drug discovery. 'Then, in 2005, I attended a lecture from a scientist who had recently returned from Oxford who introduced me to the new idea of T-cell therapy – that was Professor Rod Dunbar. It completely changed my direction. I decided to do a PhD with him and he's still my boss at the University of Auckland's School of Biological Sciences,' she says. The 46-year-old has been developing cell-based treatments for cancer for 15 years. A breakthrough treatment she helped develop for melanoma could soon be offered in clinical trials.
Otago Daily Times
7 days ago
- Otago Daily Times
No Matariki cluster but beautiful sunrise
The crowd were still treated to views of other stars and planets. PHOTOS: SUPPLIED Waitaki District Council hosted its annual stargazing event with Māori astronomer David McNamara last week as part of Matariki celebrations. Between 25 and 30 people gathered at Cape Wanbrow Lookout to try to catch a glimpse of Matariki or Puanga star clusters last Thursday morning. Unfortunately, it was mostly covered by the clouds, Waitaki District Council community educator and engagement officer Lisa Jane Potaka-Ross said. "However, other parts of the sky were clear with excellent visibility and star guide Damien McNamara was able to point out stars, planets and galaxies and share knowledge of what could be seen from a te ao Māori perspective. Clouds impeded a group from seeing Matariki or Puanga from Cape Wanbrow Lookout last week. "To close the event, those gathered sang a selection of waiata, still hoping that the beloved Matariki cluster might make a show but treated instead to the first rays of a beautiful sunrise." This was the fifth time a stargazing event has been held and Ms Potaka-Ross was pleased to see a mix of first-timers and those returning. "Clearly it is becoming a whānau tradition for some. "Numbers were slightly down but there have been several Matariki celebrations in the community this year so people are choosing which events they wish to attend to mark the occasion. "The time of Matariki, the Māori new year, and the public holiday that we now observe are coming to be celebrated by all New Zealanders as authentic and unique to our people and our place on the planet."
